-The Times of India A once-a-week medicine for diabetics — a disease that affects nearly 63 million Indians — could soon become a reality. Studies on diabetes have seen a global upsurge, with the latest data showing that bio-pharmaceutical research companies across the globe are busy developing 221 innovative new medicines. The drugs, which will help around 347 million patients include new therapies that target key abnormalities of pancreatic cells, increase Insulin secretion...

-Live Mint There are also ways in which we can help Indian institutions that have come to us seeking access to our technologies Bangalore: A key perception change is emerging in the global pharmaceutical industry on the long-established divide between the so-called generics and innovative business. While the two are still at loggerheads in several developed as well as developing markets, the world’s top drugmakers are reinventing the wheel. Paris-based Sanofi SA,...

-The Economic Times India's drug price regulator has initiated a process to end the 16-year freedom enjoyed by foreign drug makers to fix the retail price of their imported medicines in the country. The National Pharmaceutical Pricing Authority (NPPA) has written to the department of pharmaceuticals to amend the Drugs (Prices Control) Order of 1995, its chairman CP Singh told ET. The amendment will allow NPPA to seek details of the methodology adopted...

-The Business Standard State must get out of Insulin price-setting The National Pharmaceutical Pricing Authority, or NPPA, has turned down the request of drug companies to raise Insulin prices. Domestic Insulin-makers Biocon and Cadila had argued that the cost of production and packaging had become higher, and multinational corporation Eli Lilly wanted the depreciation in the rupee vis-à-vis the dollar to be factored into the price. The NPPA says it has...

Does long-term intake of a special form of Insulin prevent diabetes and heart problems, but cause cancer? The debate has been raging in medical circles for long. Now, an international study involving 12,000 pre-diabetics settles two parts of it, but leaves the other open for further research. Results of ORIGIN (Outcome Reduction with Initial Glargine Intervention) study presented in the wee hours of Tuesday at the annual meeting of the American...